Clinical Trial

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Protocol Amendment History 4 changes
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-07-16
critical Trial status changed: Recruiting → Enrolling by Invitation 2026-05-30
critical Recruitment opened 2026-04-21
notable Trial sites expanded: 0 -> 33 locations 2026-04-21
Trial Details
NCT Number NCT07458269
Lead Sponsor Kailera
Conditions Obesity
Enrollment 264 participants
Start Date 2026-03-04
Primary Completion 2027-05 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-15